Cerebrospinal fluid Aβ42/40 corresponds better than Aβ42 to amyloid PET in Alzheimer’s disease

Manuscript Number: 

16-0722R1

Author(s): 
Kaj Blennow, Paolo Eusebi, Anne M. Fagan, Johannes Kornhuber, Piotr Lewczuk, Anja Matzen, José-Luis Molinuevo, John C. Morris, Lucilla Parnetti

Disclosures

Kaj Blennow

  • Consulting Fees:
    Alzheon, Eli Lilly, Fujirebio Europe, IBL International, Novartis, Roche Diagnostics

Paolo Eusebi

  • Nothing to Disclose

Anne M. Fagan

  • Consulting Fees:
    Member of the Scientific Advisory boards for Roche, IBL International, AbbVie. Consultant for DiamiR, LabCorp

Johannes Kornhuber

  • Patents/Royalties
    Diagnosis of Alzheimer's disease. WO 2004/092737 A1, 2005. Immunoglobulin-bound Ab-peptides and immunoglobulins-binding Ab-peptides in diagnosis and therapy of Alzheimer's dementia. WO2007/082750 A1, 2007. Large Aß-peptide binding particles (LAPS) in diagnosis and therapy of Alzheimer's dementia. EP 1 811 304 A1, 2007 New formulations for diagnosis of Alzheimer's disease. WO 2011/124376 A1, 2011. Methods of differentially diagnosing dementias. EP 2437067A2, 2012.

Piotr Lewczuk

  • Consulting Fees:
    PL received consultation honoraria from Innogenetics, AJ Roboscreen GmbH, Roche, and Virion\Serion GmbH, and is a member of the Scientific Advisory Board of IBL International.
    Grants
    • Agency: 
      This study was supported by IBL International GmbH, Hamburg, Germany
      Dates: 
      2015 - 2016

Anja Matzen

  • Sponsors:
    Function: Product Development Specialist Department: Product Development

José-Luis Molinuevo

  • Consulting Fees:
    Consulting Fees: IBL International, Roche Diagnostics, Raman Health

John C. Morris

  • Consulting Fees:
    Lilly USA; Takeda Pharmaceuticals

Lucilla Parnetti

  • Consulting Fees:
    Prof. Parnetti received consultation honoraria from IBL as member of the IBL scientific advisory board